Drugs / LR20062
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06618196 | Oct 2024 → Jun 2025 overdue | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LR20062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618196 ↗ |
| Modality | Vaccine | “DTaP-HepB-IPV-Hib hexavalent vaccine LR20062” NCT06618196 ↗ |